Skip to main content

Case Comprehensive Cancer Center

Grinsztejn Receives 2024 ASH Minority Hematology Fellow Award
Eduarda Grinsztejn, MD, Case CCC Trainee Associate member, is one of nine individuals selected by the American Society of Hematology (ASH) for its 2024 ASH Minority Hematology Fellow Award (MHFA). This award encourages early-career researchers from historically underrepresented groups in the United ...
Case CCC Group Studies the Impact of Clinical Trial Design on Recruitment of Diverse Populations
An inter-organizational group of researchers and administrators from Case CCC recently published their work, "Impact of clinical trial design on recruitment of racial and ethnic minorities," in the Journal of Cancer Education. Case CCC affiliates include Population and Cancer Prevention Program memb...
Emerging Leaders Program Kick-Off Event Sparks Enthusiasm and Ideas
The inaugural class of physician-scientists gathered with Case CCC leadership to celebrate the start of the Emerging Leaders Program (ELP)—an initiative aimed at developing leaders to take Case CCC to and beyond the half-century mark. The highly competitive selection process identified 10 individua...
cancer-cells-feat
Hero Type
Image
Work by postdoc Neekkan Dey published in Molecular Cancer Research Journal
Neekkan Dey, a postdoc in the Department of Biochemistry, wrote an article accepted for publication in Molecular Cancer Research Journal by American Association for Cancer Research (AACR). Dey works in J. Alan Diehl’s group based at the Case Comprehensive Cancer Center. Dey’s study, titled “miR-21...
Cleveland GI Oncology Consortium Meeting is Doggone Successful
Presentations, collegial debates, networking, and a spirit of collaboration were the themes throughout the evening at the 2024 Cleveland Gastrointestinal (GI) Oncology Consortium Meeting planned jointly by cancer experts from University Hospitals (UH) and Cleveland Clinic (CCF) with support from the...
Exner, Basilion Receive $2.4M to Continue Work on First Prostate Cancer Cell-Targeted Ultrasound Contrast Agent
Co-leaders of Case CCC's Cancer Imaging Program, Agata Exner, PhD (PI) and James Basilion, PhD (MPI) received a four-year, $2.4M NIH grant to continue the development, implementation, and clinical translation of the first prostate cancer cell-targeted ultrasound contrast agent. The research team in...
breast-cancer-feat
Hero Type
Image
Case Western Reserve University researcher awarded $2 million federal grant to further explore possible new effective treatments for colorectal and other cancers
Funding supports newly published findings showing some medications trigger ‘cell blasters’ to kill cancer
2nd Annual Microbiome Workshop Gets High Praise
Nearly 200 people attended Case CCC's Second Annual Microbiome Workshop Feb. 7-8, 2024. The two-day event focused on the latest developments in microbiome cancer research and covered topics such as microbiome and immunity, metabolism and the microbiome, therapeutic implications of microbiome modulat...
cancer-cells-feat
Hero Type
Image
Postdoc Neekkan Dey has work accepted into Molecular Cancer Research Journal
Neekkan Dey, a postdoc in J. Alan Diehl's group in the Department of Biochemistry at Case Comprehensive Cancer Center, had work accepted for publication in the Molecular Cancer Research Journal by the American Association of Cancer Research. The study, “miR-217 regulates normal and tumor cell fate ...
Phil%20Cola%20higher%20res.jpg
Hero Type
Image
Wang Lands NIH Grant for Cancer Biology Research
Zhenghe John Wang, PhD, Chair of the Genetics and Genome Sciences Department and co-leader of Case CCC's Cancer Genomics and Epigenomics Program, was awarded a grant for $2,012,500 from National Institutes of Health/National Cancer Institute for his research titled Mechanisms of metabolic reprogramm...